Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rilmenidine: a clinical overview.

J L Reid1

  • 1Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, United Kingdom. j.l.reid@clinmed.gla.ac.uk

American Journal of Hypertension
|August 2, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995
Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995
Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995
Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995
Same journal

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same journal

Opposite Seasonal Variation in Nighttime and Morning Blood Pressure: A Longitudinal Study of Patients with Hypertension.

American journal of hypertension·2026
Same journal

Screening for Postprandial Hypotension: The Importance of Home Blood Pressure Monitoring.

American journal of hypertension·2026
Same journal

Distinct Mediating Roles of Hypertension in Arterial Stiffness Mechanisms Associated with Cardiovascular Disease Risk: A Community-Based Cohort Study.

American journal of hypertension·2026
Same journal

Long-term systolic blood pressure time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.

American journal of hypertension·2026
Same journal

Estimated Pulse Wave Velocity Predicts Outcomes After Acute Ischemic Stroke: A Multinational Cohort Analysis.

American journal of hypertension·2026
See all related articles

Rilmenidine effectively lowers blood pressure and is well-tolerated, especially in high-risk patients. It offers benefits for glucose metabolism and kidney function in specific diabetic and metabolic syndrome populations.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Rilmenidine is an antihypertensive medication targeting I1 imidazoline receptors.
  • It acts centrally to reduce sympathetic activity and in the kidney via Na+/H+ antiport inhibition.

Purpose of the Study:

  • To evaluate the antihypertensive efficacy and tolerability of rilmenidine.
  • To assess its benefits in special hypertensive populations, including those with metabolic syndrome and diabetes.

Main Methods:

  • Comparative efficacy trials against standard antihypertensives (diuretics, beta-blockers, CCBs, ACE inhibitors).
  • Clinical practice experience and observational studies in diverse hypertensive groups.
  • Analysis of metabolic parameters, left ventricular hypertrophy, and renal function (microalbuminuria).

Related Experiment Videos

Main Results:

  • Rilmenidine demonstrates comparable antihypertensive efficacy to established agents.
  • It is clinically and metabolically acceptable across various patient groups, including elderly, renal impairment, diabetes, and dyslipidemia.
  • Significant improvements in glucose metabolism and reductions in microalbuminuria were observed in specific at-risk populations.

Conclusions:

  • Rilmenidine's efficacy/tolerance profile supports its use as a first-line antihypertensive.
  • It offers particular advantages for hypertensive patients with metabolic syndrome, diabetes, and renal impairment.